ZORETIC RICHARD C

Director Zoretic buys 800 MOH shares at $125.16; holding now 8,747 shares (-64.1% from 52-week high)

Richard C. Zoretic, a director of Molina Healthcare, purchased 800 shares at $125.16 on February 11, 2026, increasing his holdings to 8,747 shares (a 10.1% increase). The purchase occurred when MOH trades at -64.1% from its 52-week high and has declined 30.0% over the past 30 days, suggesting the transaction took place during a period of significant price weakness. Zoretic's cross-ticker track record shows 8 prior open-market buys with a 42.86% 90-day win rate and average 90-day return of -0.3%, indicating his buy timing has not historically outperformed the market on this metric. The company's fundamentals show $11.5B quarterly revenue with +11.8% annual revenue growth and a 37.05 P/E ratio, though recent net income is modestly at $79.0M. This transaction is a modest-sized director purchase during material price weakness, but track record context suggests caution regarding the predictive power of the signal.

Director Richard C. Zoretic purchased 42,715 shares across 3 days for $173,306.60 at blended $4.06, raising stake 165.7%

Richard C. Zoretic, a Director at InnovAge Holding Corp., executed 3 separate purchases totaling 42,715 shares for $173,306.60 over May 28–30, 2025, at a blended average price of $4.06—substantially accumulating his position from 25,779 shares to 68,494 shares (+165.7%). This aggressive accumulation occurred across five consecutive trading days (May 16, 20–23, and May 28–30), representing a distinct pattern of discretionary open-market purchases. The company trades 35.7% below its 52-week high but has risen 30.7% over the past 30 days; however, InnovAge remains unprofitable with a net loss of $11.4M on $218.1M in quarterly revenue. His cross-ticker track record shows 5 prior buys, though none at this ticker have yet reached measurable 90-day windows. The sustained accumulation at this reduced valuation, combined with the director's willingness to deploy capital over multiple days and nearly triple his holdings, warrants attention to the underlying rationale and company fundamentals.

Director Richard C. Zoretic bought 3,045 shares across 3 transactions (5/21-5/23) for $12,308.25, blended at $4.04, raising holdings 13.4% to 25,779 shares

Director Zoretic made 3 separate purchases totaling 3,045 shares for $12,308.25 between May 21–23, 2025, at prices ranging from $3.93 to $4.13 and averaging $4.04. His holdings grew 13.4% from 22,734 to 25,779 shares. The stock currently trades at $3.93, which is -38.2% from its 52-week high of $6.36 but has rebounded +35.0% over the past 30 days and +18.4% over 90 days. InnovAge is currently unprofitable with a net loss of $-11,378,000.00 on revenue of $218,142,000.00 (latest quarter), though annual revenue grew +11.0%. This buying activity occurs at a depressed stock price relative to recent range, though Zoretic's cross-ticker track record shows only 2 prior buys and no measurable outcomes from those prior acquisitions at this ticker to establish a timing pattern.

Director Richard C Zoretic buys 2,893 shares in 2 tranches at $4.28–$4.20; holds 22,734 shares post-purchase.

Richard C Zoretic, a director at InnovAge Holding Corp., executed 2 purchases totaling 2,893 shares for $12,317.48 at a blended average price of $4.26 on May 16 and May 20, 2025. His holdings increased 14.6% relative to pre-transaction holdings of 19,841 shares. The company reported latest-quarter revenue of $218,142,000.00 but a net loss of $-11,378,000.00, and was unprofitable over its most recent full fiscal year. The stock is currently trading at $4.24, down 33.3% from its 52-week high of $6.36 and up 54.2% over the preceding 30 days. The purchase price proximity to current price and the timing relative to recent price momentum merit monitoring of INNV's financial trajectory.